<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2022-11-1-40-49</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1160</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПОИСК И РАЗРАБОТКА НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH AND DEVELOPMENT OF NEW DRUG PRODUCTS</subject></subj-group></article-categories><title-group><article-title>Синтез N-ацилфенилацетамидов и N-ацил-β-кетоамидов и их влияние на ЦНС</article-title><trans-title-group xml:lang="en"><trans-title>Synthesis and Action of N-acylphenylacetamides and N-acyl-β-ketoamides on the Central Nervous System</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1333-3472</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кодониди</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kodonidi</surname><given-names>I. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>357532, Россия, г. Пятигорск, пр. Калинина, д. 11</p></bio><bio xml:lang="en"><p>11, Kalinina av., Pyatigorsk, 357532, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0566-1134</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аненко</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Anenko</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аненко Денис С.</p><p>357532, Россия, г. Пятигорск, пр. Калинина, д. 11</p></bio><bio xml:lang="en"><p>Denis S. Anenko</p><p>11, Kalinina av., Pyatigorsk, 357532, Russia</p></bio><email xlink:type="simple">anencko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0889-7855</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поздняков</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Pozdnyakov</surname><given-names>D. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>357532, Россия, г. Пятигорск, пр. Калинина, д. 11</p></bio><bio xml:lang="en"><p>11, Kalinina av., Pyatigorsk, 357532, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пятигорский медико-фармацевтический институт – филиал ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ПМФИ – филиал ФГБОУ ВО ВолгГМУ Минздрава России)</institution></aff><aff xml:lang="en"><institution>Pyatigorsk Medical Pharmaceutical Institute – branch of Volgograd State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>02</month><year>2022</year></pub-date><volume>11</volume><issue>1</issue><fpage>40</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кодониди И.П., Аненко Д.С., Поздняков Д.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Кодониди И.П., Аненко Д.С., Поздняков Д.И.</copyright-holder><copyright-holder xml:lang="en">Kodonidi I.P., Anenko D.S., Pozdnyakov D.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1160">https://www.pharmjournal.ru/jour/article/view/1160</self-uri><abstract><sec><title>Введение</title><p>Введение. Одним из перспективных направлений поиска биологически активных соединений является молекулярное конструирование биологически активных соединений, содержащих заведомо значимый фармакоформный фрагмент. В данной статье в качестве центроида (scaffold) для поиска биологически активных соединений рассматриваются производные фенилуксусной кислоты. Однако особый интерес представляет производное фенилацетамид, его фрагмент входит в строение препарата атенолола. Оптимизация методов синтеза N-ацилфенилацетамидов и N-ацил-β-кетоамидов позволит расширить границы молекулярного конструирования и целенаправленного синтеза биологически активных веществ, содержащих в качестве центроида фрагмент фенилуксусной кислоты.</p></sec><sec><title>Цель</title><p>Цель. Оптимизировать методы синтеза N-ацилфенилацетамидов и N-ацил-β-кетоамидов и выявить фармакологическое влияние синтезированных соединений на ЦНС.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Получение целевых N-ацилфенилацетамидов осуществлялось путем взаимодействия 2-фенилацетамида с ангидридами карбоновых кислот в условиях кислотного катализа. Следующим этапом синтеза являлось получение N-ацил-β-кетоамидов взаимодействием синтезированных N-ацилфенилацетамидов с ангидридами карбоновых кислот в присутствии катализатора трифторида бора диацетата. Строение полученных соединений подтверждено ИК-, 1H ЯМР-спектрометрией. Индивидуальность и чистоту полученных соединений контролировали тонкослойной хроматографией. Исследование синтезированных соединений на ЦНС осуществлялось в тестах «УРПИ», «ТЭИ» и «Водный лабиринт Морриса».</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В результате исследования синтезированы N-ацилфенилацетамиды и N-ацил-β-кетоамиды. Суть оптимизации методики синтеза N-ацилфенилацетамидов является в замене хлорной 65 % на концентрированную серную кислоту. В 1H ЯМР-спектрах, подтверждающих структуры синтезированных соединений выявлены важные характерные признаки для N-ацетил-3-оксо-2- фенилпентанамида (VI) и N-ацетил-3-оксо-2-фенилгексанамида (VIII), содержащие хиральный центр. Полученные вещества обладают выраженным влиянием на ЦНС, их ноотропная активность заключается в уменьшении выраженности сенсомоторных нарушений у животных. В результате исследования выявлены соединения-лидеры, превосходящие действие препарата сравнения пирацетам.</p></sec><sec><title>Заключение</title><p>Заключение. Осуществлённое исследование подтверждает целесообразность поиска высокоэффективных и безопасных ноотропных средств в ряду ацилированных производных амида фенилуксусной кислоты.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. One of the most promising directions in the search for biologically active compounds is the molecular design of biologically active compounds containing a known pharmacoform fragment. In this article, phenylacetic acid derivatives are considered as a scaffold for the search for biologically active compounds. However, the phenylacetamide derivative is of particular interest, its fragment is included in the structure of the atenolol drug. Optimization of methods for the synthesis of N-acylphenylacetamides and N-acyl-β-ketoamides will expand the boundaries of molecular design and targeted synthesis of biologically active substances containing a phenylacetic acid fragment as a centroid.</p></sec><sec><title>Aim</title><p>Aim. Obtain N-acylphenylacetamides and N-acyl-β-ketoamides, optimize the synthesis and isolation methods, and establish the degree of manifestation of the psychotropic activity of the compounds.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Obtaining the target N-acylphenylacetamides was carried out by the interaction of 2-phenylacetamide with carboxylic acid anhydrides under conditions of acid catalysis. The next stage of the synthesis was the preparation of N-acyl-β-ketoamides by the interaction of the synthesized N-acylphenylacetamides with carboxylic acid anhydrides in the proposed catalyst for boron trifluoride diacetate. The structure of the compounds was confirmed by IR, 1H NMR spectrometry. The individuality and purity of the obtained compounds were monitored by thin layer chromatography. The study of the synthesized compounds on the central nervous system was carried out in the tests "Conditioned reflex of passive avoidance – CPAR", "Extrapolation escape (ETI)", "Morris water maze" and "Beam Walking".</p></sec><sec><title>Results and discussion</title><p>Results and discussion. As a result of the research, N-acylphenylacetamides and N-acyl-β-ketoamides were synthesized. The essence of the optimization of the procedure for the synthesis of N-acylphenylacetamides is to replace chloric 65 % with concentrated sulfuric acid. The 1H NMR spectra confirming the structures of the synthesized compounds revealed important characteristic features for N-acetyl-3-oxo-2- phenylpentanamide (VI) and N-acetyl-3-oxo-2-phenylhexanamide (VIII) containing a chiral center. The resulting substances have a pronounced effect on the central nervous system, their nootropic activity is to reduce the severity of sensorimotor disorders in animals. As a result of the study, the leading compounds were identified, superior to the effect of the reference drug piracetam.</p></sec><sec><title>Conclusion</title><p>Conclusion. The carried out research confirms the expediency of searching for highly effective and safe nootropic agents in the series of acylated derivatives of phenylacetic acid amide.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>N-ацилфенилацетамиды</kwd><kwd>N-ацил-β-кетоамиды</kwd><kwd>пиримидин-4(1H)-оны</kwd><kwd>ноотропная активность</kwd><kwd>хиральный центр</kwd><kwd>диастеротопные протоны</kwd><kwd>пирацетам</kwd></kwd-group><kwd-group xml:lang="en"><kwd>N-acylphenylacetamides</kwd><kwd>N-acyl-β-ketoamides</kwd><kwd>pyrimidin-4(1H)-one</kwd><kwd>nootropic activity</kwd><kwd>chiral center</kwd><kwd>diastereotopic protons</kwd><kwd>piracetam</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Машковский М. Д. Лекарственные средства. 15-е изд. М.: ООО «Издательство Новая Волна»; 2005. 169 c.</mixed-citation><mixed-citation xml:lang="en">Mashkovskij M. D. Lekarstvennye sredstva [Medicinal products]. 15th ed. Moscow: LLC "Izdatel’stvo Novaja Volna"; 2005. 169 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Вартанян Р. С. Синтез основных лекарственных средств. М.: Медицинское информационное агенство; 2004. 233 с.</mixed-citation><mixed-citation xml:lang="en">Vartanjan R. S. Sintez osnovnyh lekarstvennyh sredstv [Synthesis of basic medicines]. Moscow: Medicinskoe informacionnoe agenstvo; 2004. 233 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Орлов В. Д., Липсон В. В., Иванов В. В. Медицинская химия. Харьков: Фолио; 2005. 193 с.</mixed-citation><mixed-citation xml:lang="en">Orlov V. D., Lipson V. V., Ivanov V. V. Medicinskaja himija [Medicinal chemistry]. Kharkov: Folio; 2005. 193 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Воронков А. В., Поздняков Д. И., Мирошниченко К. А., Потапова А. А., Кодониди И. П., Аненко Д. С. Производные пиримидина – перспективные корректоры метаболических и функциональных нарушений головного мозга в условиях хронической травматической энцефалопатии. Вестник смоленской государственной медицинской академии. 2019;18(3):18–24.</mixed-citation><mixed-citation xml:lang="en">Voronkov A. V., Pozdnyakov D. I., Miroshnichenko K. A., Potapova A. A., Kodonidi I. P., Anenko D. S. Pyrimidine derivatives are promising correctors of metabolic and functional disorders of the brain in conditions of chronic traumatic encephalopathy. Vestnik Smolenskoy Gosudarstvennoy Medicinskoy Akademii. 2019;18(3):18–24. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Кодониди И. П., Аненко Д. С., Терехов А. Ю., Сидорская С. Ю., Григорянц Э. Г. Синтез 2,6-диалкильных производных пиримидин-4(1h)-она, обладающих противовоспалительным действием. Фармация. 2021;70(1):11–17. DOI: 10.29296/25419218-2021-01-02.</mixed-citation><mixed-citation xml:lang="en">Kodonidi I. P., Anenko D. S., Terehov A. J., Sidorskaja S. J., Grigorjanc J. G. Synthesis of 2,6-dialkyl derivatives of pyrimidine-4 (1h)-one with an anti-inflammatory effect. Farmatsiya. 2021;70(1):11–17. (In Russ.) DOI: 10.29296/25419218-2021-01-02.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kim K., Kim D., Lee H., Lee T. H., Kim K-Y., Kim H. New Pyrimidinone-Fused 1,4-Naphthoquinone Derivatives Inhibit the Growth of Drug Resistant Oral Bacteria. Biomedicines. 2020;8(6)160. DOI: 10.3390/biomedicines8060160.</mixed-citation><mixed-citation xml:lang="en">Kim K., Kim D., Lee H., Lee T. H., Kim K-Y., Kim H. New Pyrimidinone-Fused 1,4-Naphthoquinone Derivatives Inhibit the Growth of Drug Resistant Oral Bacteria. Biomedicines. 2020;8(6)160. DOI: 10.3390/biomedicines8060160.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kelada M., Walsh J. M. D., Devine R. W., McArdle P., Stephens J. C. Synthesis of pyrazolopyrimidinones using a "one-pot" approach under microwave irradiation. Beilstein Journal of Organic Chemistry. 2018;14:1222–1228. DOI: 10.3762/bjoc.14.104.</mixed-citation><mixed-citation xml:lang="en">Kelada M., Walsh J. M. D., Devine R. W., McArdle P., Stephens J. C. Synthesis of pyrazolopyrimidinones using a "one-pot" approach under microwave irradiation. Beilstein Journal of Organic Chemistry. 2018;14:1222–1228. DOI: 10.3762/bjoc.14.104.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">MacDonald J. A., Sutherland C., Carlson D. A., Bhaidani S., Al-Ghabkari A., Sward K., Haystead T. A. J., Walsh M. P. A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle. Molecular Pharmacology. 2016;89(1):105–117. DOI: 10.1124/mol.115.100529.</mixed-citation><mixed-citation xml:lang="en">MacDonald J. A., Sutherland C., Carlson D. A., Bhaidani S., Al-Ghabkari A., Sward K., Haystead T. A. J., Walsh M. P. A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle. Molecular Pharmacology. 2016;89(1):105–117. DOI: 10.1124/mol.115.100529.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Elsharif A. M. Synthesis of New Pyrimidinone Derivatives and Their Respective Biological Structure Assessment. Orient Journal of Chemistry. 2019;35(2):658–667. DOI: 10.13005/ojc/350221.</mixed-citation><mixed-citation xml:lang="en">Elsharif A. M. Synthesis of New Pyrimidinone Derivatives and Their Respective Biological Structure Assessment. Orient Journal of Chemistry. 2019;35(2):658–667. DOI: 10.13005/ojc/350221.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bederson J. B., Pitts L. H., Tsuji M., Nishimura M. C., Davis R. L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–476.</mixed-citation><mixed-citation xml:lang="en">Bederson J. B., Pitts L. H., Tsuji M., Nishimura M. C., Davis R. L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–476.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen P. A., Zakharevich I., Gerona R. Presence of Piracetam in Cognitive Enhancement Dietary Supplements. JAMA Internal Medicine. 2019;180(3):458–459. DOI: 10.1001/jamainternmed.2019.5507.</mixed-citation><mixed-citation xml:lang="en">Cohen P. A., Zakharevich I., Gerona R. Presence of Piracetam in Cognitive Enhancement Dietary Supplements. JAMA Internal Medicine. 2019;180(3):458–459. DOI: 10.1001/jamainternmed.2019.5507.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Keil U., Scherping I., Hauptmann S., Schuessel K., Eckert A., Müller W. E. Piracetam improves mitochondrial dysfunction following oxidative stress. British Journal of Pharmacology. 2005;147(2):199–208. DOI:10.1038/sj.bjp.0706459.</mixed-citation><mixed-citation xml:lang="en">Keil U., Scherping I., Hauptmann S., Schuessel K., Eckert A., Müller W. E. Piracetam improves mitochondrial dysfunction following oxidative stress. British Journal of Pharmacology. 2005;147(2):199–208. DOI:10.1038/sj.bjp.0706459.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Миронов А. Н., ред. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К; 2012. 944 с.</mixed-citation><mixed-citation xml:lang="en">Mironov A. N., editor. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv [Guidelines for conducting preclinical studies of drugs]. Part One. Moscow: Grif i K; 2012. 944 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fleming S. M, Ekhator O. R., Ghisays V. Assessment of Sensorimotor Function in Mouse Models of Parkinson’s Disease. Journal of Visualized Experiments. 2013;76:50303. DOI: 10.3791/50303.</mixed-citation><mixed-citation xml:lang="en">Fleming S. M, Ekhator O. R., Ghisays V. Assessment of Sensorimotor Function in Mouse Models of Parkinson’s Disease. Journal of Visualized Experiments. 2013;76:50303. DOI: 10.3791/50303.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Плотникова Е. Ю., Грачева Т. Ю., Синьков М. А., Сухих А. С. Анализ ошибок при проведении сравнительных исследований клинической и экономической эффективности на примере дженериков урсодезоксихолевой кислоты. РМЖ. 2019;27(5):3–7.</mixed-citation><mixed-citation xml:lang="en">Plotnikova E. Y., Gracheva T. Y., Sinkov M. A., Sukhikh A. S. Error analysis in comparative studies of clinical and economic efficiency using the ursodeoxycholic acid generics example. RMJ. 2019;27(5):3–7. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi M., Bachman S., Hashimoto S., Eichman C. C., Stoltz B. M. Ni-Catalysed Enantioselective C-Acylation of α-substituted Lactams. Journal of the American Chemical Society. 2016;138(29):8997–9000. DOI: 10.1021/jacs.6b02120.</mixed-citation><mixed-citation xml:lang="en">Hayashi M., Bachman S., Hashimoto S., Eichman C. C., Stoltz B. M. Ni-Catalysed Enantioselective C-Acylation of α-substituted Lactams. Journal of the American Chemical Society. 2016;138(29):8997–9000. DOI: 10.1021/jacs.6b02120.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Moradian M., Amini A., Naeimi H. Zncl2@MWCNTs nanocomposite as an efficient and reusable catalyst for direct regioselective ortho C-acylation of phenolic compounds under solvent-free and microwave conditions. Green Chemistry Letters and Reviews. 2017;10(4):228–234. DOI: 10.1080/17518253.2017.1349194.</mixed-citation><mixed-citation xml:lang="en">Moradian M., Amini A., Naeimi H. Zncl2@MWCNTs nanocomposite as an efficient and reusable catalyst for direct regioselective ortho C-acylation of phenolic compounds under solvent-free and microwave conditions. Green Chemistry Letters and Reviews. 2017;10(4):228–234. DOI: 10.1080/17518253.2017.1349194.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J., Hong M., Jung Y., Cho E., Rhee H. Synthesis of 1,3,5-trisubstituted-1,2,4-triazoles by microwave-assisted N-acylation of amide derivatives and the consecutive reaction with hydrazine hydrochlorides. Tetrahedron. 2012;68(8):2045–2051.</mixed-citation><mixed-citation xml:lang="en">Lee J., Hong M., Jung Y., Cho E., Rhee H. Synthesis of 1,3,5-trisubstituted-1,2,4-triazoles by microwave-assisted N-acylation of amide derivatives and the consecutive reaction with hydrazine hydrochlorides. Tetrahedron. 2012;68(8):2045–2051.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Li W., Zheng Y., Qu E., Bai J. β-Keto Amides: A Jack-of-All-Trades Building Block in Organic Chemistry. European Journal of Organic Chemistry. 2021;37:5151–5192. DOI: 10.1002/ejoc.202100692.</mixed-citation><mixed-citation xml:lang="en">Li W., Zheng Y., Qu E., Bai J. β-Keto Amides: A Jack-of-All-Trades Building Block in Organic Chemistry. European Journal of Organic Chemistry. 2021;37:5151–5192. DOI: 10.1002/ejoc.202100692.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Оспанов М. А., Турмуханова М. Ж., Мурзагулова К. Б., Абилов Ж. А. Стереохимические особенности непредельных аминодиэфиров – полупродуктов в синтезе рихлокаина. Вестник КазНУ. Серия химическая. 2014;3(75):361–368. DOI: 10.15328/chemb_2014_361-68.</mixed-citation><mixed-citation xml:lang="en">Ospanov M. A., Turmuhanova M. Z., Murzagulova K. B., Abilov Z. A. Stereochemical features of unsaturated aminodiesters – intermediates in the synthesis of Richlocaine. Vestnik KazNU. Seriya khimicheskaya = Chemical Bulletin of Kazakh National University. Serija himicheskaja. 2014;3(75):361–368. (In Russ.) DOI: 10.15328/chemb_2014_361-68.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Терней А. Л. Современная органическая химия. Пер. с англ. В 2 томах. 2 том. М.: Мир; 1981. C. 559–561.</mixed-citation><mixed-citation xml:lang="en">Terney A. L. Sovremennaya organicheskaya khimiya [Modern organic chemistry]. In 2 volumes. 2 volume. Moscow: Mir; 1981. 559–561 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Пакальнис В. В., Зерова И. В., Якимович С. И. Взаимодействие ароил- и гетероароилтрифторацетонов с ацилгидразинами: регионаправленность и таутомерия продуктов конденсации. ЖОХ. 2007;77:1665–1676.</mixed-citation><mixed-citation xml:lang="en">Pakal’nis V. V., Zerova I. V., Jakimovich S. I. Interaction of aroyland heteroaroyltrifluoroacetones with acylhydrazines: regional orientation and tautomerism of condensation products. Zhurnal organicheskoj himii. 2007;77:1665–1676. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Мещерякова С. А. Синтез, свойства, структура и биологическая активность новых S и N-производных пиримидина. Дис. ... докт. фарм. наук. Уфа; 2015. 205 с. Доступно по: https://www.dissercat.com/content/sintez-svoistva-struktura-i-biologicheskaya-aktivnost-novykh-s-i-n-proizvodnykh-pirimidina. Ссылка активна на 29.12.2021.</mixed-citation><mixed-citation xml:lang="en">Meshcheryakova S. A. Sintez, svojstva, struktura i biologicheskaja aktivnost’ novyh S i N-proizvodnyh pirimidina [Synthesis, properties, structure and biological activity of new S and N-pyrimidine derivatives] [dissertation]. Ufa; 2015. 205 p. Available at: https://www.dissercat.com/content/sintez-svoistva-strukturai-biologicheskaya-aktivnost-novykh-s-i-n-proizvodnykhpirimidina. Accessed: 29.12.2021. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
